CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer diagnosis and therapy selection, today announced results from a study conducted with Duke University and recently published in Blood Advances. The study demonstrated the value of broad structural rearrangement profiling in diffuse large B-cell lymphoma (DLBCL), with Arima Hi-C technology identifying clinically important rearrangements missed or not
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
